Teva Sees COVID Sales Correction

Takes Impairment On Japanese Venture And Bolsters Biosimilars Business

In a busy second quarter for Teva, a COVID-19 slump acted as a correction to the related boost in demand seen in the first quarter of 2020.

Balancing_Coins_Covid
A Q2 decline due to COVID-19 balanced out a spike in demand from Q1 • Source: Shutterstock

A slump in sales due to COVID-19, a significant reorientation of strategy in Japan, continued pressures over US investigations into price-fixing, a major biosimilars deal and a key new respiratory launch meant there was plenty to talk about during Teva’s presentation of its second-quarter results this week.

“During the quarter, we experienced lower sales of our generic and OTC products in all regions,” acknowledged Teva’s president and...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business